drugset / Trial / NCT01163487

Metabolic Reprogramming Therapy for Treatment of Recurrent Head and Neck Cancers

NCT01163487

Phase 1 Completed 17 enrolled Daniel T. Chang
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to study the effect of the drug DCA (dichloroacetate) on recurrent head and neck cancers. Part of this study will also use EF5 PET scan to study tumor hypoxia.

Timeline

Start
2010-08
Primary completion
2015-02
Completion
2016-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Dichloroacetate Small molecule 25 mg/kg Oral
Subject Dichloroacetate Small molecule 37.5 mg/kg Oral
Subject Dichloroacetate Small molecule 50 mg/kg Oral

Indications